Profound Medical Corp.
PROF
$6.32
-$0.11-1.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 171.96% | 125.56% | 561.68% | 520.87% | 251.15% |
| Total Other Revenue | 33.22% | 30.50% | 26.28% | 20.44% | 24.89% |
| Total Revenue | 62.41% | 53.45% | 68.06% | 41.81% | 32.05% |
| Cost of Revenue | 13.08% | 16.69% | 35.26% | 24.27% | 33.53% |
| Gross Profit | 96.01% | 79.50% | 91.32% | 53.68% | 31.06% |
| SG&A Expenses | 41.73% | 54.91% | 38.49% | 24.60% | 35.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.30% | 40.50% | 32.05% | 21.82% | 29.03% |
| Operating Income | -27.17% | -37.41% | -23.83% | -16.80% | -28.28% |
| Income Before Tax | -26.07% | -47.31% | -14.27% | 1.27% | -8.71% |
| Income Tax Expenses | -271.43% | 128.95% | 99.26% | 98.44% | -97.72% |
| Earnings from Continuing Operations | -26.00% | -48.27% | -14.82% | 0.84% | -7.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.00% | -48.27% | -14.82% | 0.84% | -7.60% |
| EBIT | -27.17% | -37.41% | -23.83% | -16.80% | -28.28% |
| EBITDA | -28.31% | -38.83% | -24.50% | -16.85% | -28.82% |
| EPS Basic | -0.75% | -20.22% | 4.40% | 14.86% | 3.73% |
| Normalized Basic EPS | -0.79% | -19.38% | 4.92% | 15.27% | -6.73% |
| EPS Diluted | -0.75% | -20.22% | 4.40% | 14.86% | 3.73% |
| Normalized Diluted EPS | -0.79% | -19.38% | 4.92% | 15.27% | -6.73% |
| Average Basic Shares Outstanding | 22.54% | 20.82% | 18.94% | 16.89% | 12.35% |
| Average Diluted Shares Outstanding | 22.54% | 20.82% | 18.94% | 16.89% | 12.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |